Schizophrenia Research
Volume 100, Issue 1 , Pages 86-96 , March 2008

An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients

  • Daniel J. Abrams

      Affiliations

    • Department of Psychiatry, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, United States
    • ,
  • Lijun Zheng

      Affiliations

    • Department of Psychiatry, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, United States
    • ,
  • Kevin S. Choo

      Affiliations

    • Department of Psychiatry, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, United States
    • ,
  • Jun J. Yang

      Affiliations

    • School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, United States
    • ,
  • Wei Wei

      Affiliations

    • Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, United States
    • ,
  • Thomas J. Anchordoquy

      Affiliations

    • School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, United States
    • ,
  • Nasser H. Zawia

      Affiliations

    • Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, United States
    • ,
  • Karen E. Stevens

      Affiliations

    • Department of Psychiatry, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045, United States
    • Medical Research, Veterans Affairs Medical Center, Denver CO, United States
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, MS 8344, University of Colorado at Denver and Health Sciences Center, PO Box 5611, Aurora, CO 80045, United States. Tel.: +1 303 724 4423; fax: +1 303 724 4425.

Received 16 July 2007 ,Revised 19 October 2007 ,Accepted 24 October 2007.

References 

  1. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull. 1998;24(2):189–202
  2. Alvir JM, Lieberman JA, Saffermanm AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med. 1993;329(3):162–167
  3. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br. J. Psychiatry. 1996;169(4):483–488
  4. Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am. J. Psychiatry. 2001;158(8):1305–1313
  5. Ballantyne JC, Carwood CM. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst. Rev. 2005;25(1):CD005178
  6. Brambilla P, Barale F, Caverzasi E, Tognoni T, Barui C. Clozapine-treated subjects with treatment-resistant schizophrenia: a systemic review of experimental and observational studies. Int. Clin. Psychopharmacol. 2002;17(4):189–195
  7. Brier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, et al. Effects of clozapine in schizophrenic outpatients: effects on positive and negative symptoms. Arch. Gen. Psychiatry. 1994;151(1):20–26
  8. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry. 1998;155(6):751–760
  9. Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, et al. The risks and benefits of clozapine versus chlorpromazine. J. Clin. Psychopharmacol. 1987;7(6):377–384
  10. Croft RJ, Lee A, Bertolot J, Gruzelier JH. Associations of P50 suppression and desensitization with perceptual and cognitive features of “unreality” in schizotypy. Biol. Psychiatry. 2001;50(6):441–446
  11. Cullum CM, Harris JG, Waldo MC, Smeroff E, Madison A, Nagamoto HT, et al. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr. Res. 1993;10(2):131–141
  12. Dones I. Intrathecal baclofen for the treatment of spasticity. Acta Neurochir. Suppl. 2007;97(Pt 1):185–188
  13. Donohue M, Wei W, Wu J, Zawia NH, Hyd N, De Jesus V, et al. Characterization of nigerlysin, hemolysin produced by Apergillus niger, and effect on mouse neuronal cells in vitro. Toxicol. 2006;219(1-3):150–155
  14. Erwin RJ, Turetsky BI, Moberg P, Gur RC, Gur RG. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr. Res. 1998;33(3):157–167
  15. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol. Bull. 1996;32(4):683–697
  16. Fleischhaker C, Schulz E, Tepper K, Martin M, Hennighausen K, Remschmidt H. Long-term course of adolescent schizophrenia. Schizophr. Bull. 2005;31(3):769–780
  17. Gardner I, Leeder JS, Chin T, Zahid N, Uetrecht JP. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol. Pharmacol. 1998;53(6):999–1008
  18. Hasan NY, Elkawy MA, Elzeany BE, Wagieh NE. Stability indicating methods for the determination of clozapine. J. Pharm. Biomed. Anal. 2002;30(1):35–47
  19. Hashimoto K, Iyo M, Freedman R, Stegens KE. Tropisetron improves deficient inhibitory auditory processing in DBA/2 mice: role of α7 nicotinic acetylcholine receptors. Psychopharmacol. 2005;183(1):13–19
  20. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a clinical review of adverse effects and management. Ann. Clin. Psychiatry. 2003;15(1):33–48
  21. Jang J, Yaksh TL, Hill HF. Use of 2-hydroxypropyl-beta-cyclodextrin as an intrathecal drug vehicle with opioids. J. Pharmacol. Exp. Ther. 1992;261(2):592–600
  22. Kapur S, Vanderspek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 2003;305(2):625–631
  23. Koulousakis A, Kuchta J, Bayarassou A, Sturm V. Intrathecal opioids for intractable pain syndromes. Acta Neurochir. Suppl. 2007;97(pt 1):43–48
  24. Levy R. Implanted drug delivery systems for control of chronic pain. Chapter 19 of Neurosurgical Management of Pain. New York, NY: Springer-Verlag; 1997;
  25. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am. J. Psychiatry. 1993;157(5):767–771
  26. Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int. Clin. Psychopharmacol. 2005;20(4):183–198
  27. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry. 2006;163(4):600–610
  28. Miller DD. Review and management of clozapine side effects. J. Clin. Psychiatry. 2000;61(Suppl 8):14–17
  29. Miller CL, Freedman R. The activity of hippocampal interneurons and pyramidal cells during the response of the hippocampus to repeated auditory stimuli. Neurosci. 1995;69:371–381
  30. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol. Psychiatry. 1996;40(3):181–188
  31. Nagamoto HT, Adler LE, McRae KA, Heuttl P, Cawthra E, Gerhardt G, et al. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-hydroxyphenylglycol. Neuropsychobiology. 1999;39(1):10–17
  32. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry. 2006;63(6):630–638
  33. Overstreet DH, Commissaris RC, De La Garza R, File SE, Knapp DJ, Seiden LS. Involvement of 5-HT1A receptors in animal tests of anxiety and depression: evidence from genetic models. Stress. 2003;6(2):101–110
  34. Powell CM, Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. Biol. Psychiatry. 2006;59(12):1198–1207
  35. Radek RJ, Miner HM, Bratcher NA, Decker MW, Goplalakrishnan M, Bitner RS. Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating. Psychopharmacol. (Berl). 2006;187(1):47–55
  36. Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr. Serv. 1998;49(8):1029–1033
  37. Richard I, Menei P. Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders. Acta Neurochir. Suppl. 2007;97(Pt 1):213–218
  38. Serralta A, Barcia JA, Ortiz P, Duran C, Hernandez ME, Alos M. Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model. Epilepsy Res. 2006;70(1):15–26
  39. Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacol. 2002;26(5):583–594
  40. Simosky JK, Stevens KE, Adler LE, Freedman R. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacol. 2003;165(4):386–396
  41. Stevens KE, Freedman R, Collins AC, Hall M, Leonard S, Marks MJ, et al. Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neurospychopharmacol. 1996;15(2):152–162
  42. Stevens KE, Kem WR, Mahnir VM, Freedman R. Selective alpha-7 nicotinic agonists normalize inhibition of auditory response in DBA/2 mice. Psychopharmacol. 1998;136(4):320–327
  43. Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am. J. Psychiatry. 2004;161(9):1620–1625
  44. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry. 2002;159(2):255–262
  45. Yaksh TL. Spinal systems and pain processing: development of novel analgesic drugs with mechanistically defined models. Trends Pharmacol. Sci. 1999;20(8):329–337
  46. Yaksh TL, Jang JD, Nishiuchi Y, Braun KP, Ro SG, Goodman M. The utility of 2-hydroxypropyl-beta-cyclodextrin as a vehicle for the intracerebral and intrathecal administration of drugs. Life Sci. 1991;48(7):623–633

PII: S0920-9964(07)00470-7

doi: 10.1016/j.schres.2007.10.012

Schizophrenia Research
Volume 100, Issue 1 , Pages 86-96 , March 2008

Article Tools

* Image Usage & Resolution